Lactonization

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform

Matthias Schwab - One of the best experts on this subject based on the ideXlab platform.

  • udp glucuronosyltransferase ugt polymorphisms affect atorvastatin Lactonization in vitro and in vivo
    Clinical Pharmacology & Therapeutics, 2010
    Co-Authors: Stephan Riedmaier, Kathrin Klein, Ute Hofmann, Jenni E. Keskitalo, Pertti J. Neuvonen, Matthias Schwab
    Abstract:

    The response to statins shows large interpatient variability. Atorvastatin δ-lactone is pharmacologically inactive but has been associated with toxicity. We investigated the role of UDP-glucuronosyltransferases (UGTs) in atorvastatin Lactonization. In human liver microsomes, Lactonization was correlated with UGT1A3 (rs = 0.61, P < 0.0001) but not with UGT1A1. Surprisingly, lactone formation was significantly higher in carriers of UGT1A1*28, an allele that is associated with lower UGT1A1 expression. We show that this inverse correlation is due to extensive linkage disequilibrium in the UGT1A locus and that several UGT1A3 haplotypes are associated with strong increases in UGT1A3 expression in vitro. Analyses of the pharmacokinetic parameters of atorvastatin and metabolites in genotyped volunteers confirmed that there is an increase in atorvastatin Lactonization in carriers of UGT1A3*2 in vivo. The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation. Clinical Pharmacology & Therapeutics (2010) 87 1, 65–73. doi:10.1038/clpt.2009.181

  • UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo
    Clinical pharmacology and therapeutics, 2009
    Co-Authors: Stephan Riedmaier, Kathrin Klein, Ute Hofmann, Jenni E. Keskitalo, Pertti J. Neuvonen, Matthias Schwab, Mikko Niemi, Ulrich M. Zanger
    Abstract:

    The response to statins shows large interpatient variability. Atorvastatin δ-lactone is pharmacologically inactive but has been associated with toxicity. We investigated the role of UDP-glucuronosyltransferases (UGTs) in atorvastatin Lactonization. In human liver microsomes, Lactonization was correlated with UGT1A3 (rs = 0.61, P < 0.0001) but not with UGT1A1. Surprisingly, lactone formation was significantly higher in carriers of UGT1A1*28, an allele that is associated with lower UGT1A1 expression. We show that this inverse correlation is due to extensive linkage disequilibrium in the UGT1A locus and that several UGT1A3 haplotypes are associated with strong increases in UGT1A3 expression in vitro. Analyses of the pharmacokinetic parameters of atorvastatin and metabolites in genotyped volunteers confirmed that there is an increase in atorvastatin Lactonization in carriers of UGT1A3*2 in vivo. The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation. Clinical Pharmacology & Therapeutics (2010) 87 1, 65–73. doi:10.1038/clpt.2009.181

Apparao Satyam - One of the best experts on this subject based on the ideXlab platform.

Jian Zhou - One of the best experts on this subject based on the ideXlab platform.

Stephan Riedmaier - One of the best experts on this subject based on the ideXlab platform.

  • udp glucuronosyltransferase ugt polymorphisms affect atorvastatin Lactonization in vitro and in vivo
    Clinical Pharmacology & Therapeutics, 2010
    Co-Authors: Stephan Riedmaier, Kathrin Klein, Ute Hofmann, Jenni E. Keskitalo, Pertti J. Neuvonen, Matthias Schwab
    Abstract:

    The response to statins shows large interpatient variability. Atorvastatin δ-lactone is pharmacologically inactive but has been associated with toxicity. We investigated the role of UDP-glucuronosyltransferases (UGTs) in atorvastatin Lactonization. In human liver microsomes, Lactonization was correlated with UGT1A3 (rs = 0.61, P < 0.0001) but not with UGT1A1. Surprisingly, lactone formation was significantly higher in carriers of UGT1A1*28, an allele that is associated with lower UGT1A1 expression. We show that this inverse correlation is due to extensive linkage disequilibrium in the UGT1A locus and that several UGT1A3 haplotypes are associated with strong increases in UGT1A3 expression in vitro. Analyses of the pharmacokinetic parameters of atorvastatin and metabolites in genotyped volunteers confirmed that there is an increase in atorvastatin Lactonization in carriers of UGT1A3*2 in vivo. The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation. Clinical Pharmacology & Therapeutics (2010) 87 1, 65–73. doi:10.1038/clpt.2009.181

  • UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo
    Clinical pharmacology and therapeutics, 2009
    Co-Authors: Stephan Riedmaier, Kathrin Klein, Ute Hofmann, Jenni E. Keskitalo, Pertti J. Neuvonen, Matthias Schwab, Mikko Niemi, Ulrich M. Zanger
    Abstract:

    The response to statins shows large interpatient variability. Atorvastatin δ-lactone is pharmacologically inactive but has been associated with toxicity. We investigated the role of UDP-glucuronosyltransferases (UGTs) in atorvastatin Lactonization. In human liver microsomes, Lactonization was correlated with UGT1A3 (rs = 0.61, P < 0.0001) but not with UGT1A1. Surprisingly, lactone formation was significantly higher in carriers of UGT1A1*28, an allele that is associated with lower UGT1A1 expression. We show that this inverse correlation is due to extensive linkage disequilibrium in the UGT1A locus and that several UGT1A3 haplotypes are associated with strong increases in UGT1A3 expression in vitro. Analyses of the pharmacokinetic parameters of atorvastatin and metabolites in genotyped volunteers confirmed that there is an increase in atorvastatin Lactonization in carriers of UGT1A3*2 in vivo. The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation. Clinical Pharmacology & Therapeutics (2010) 87 1, 65–73. doi:10.1038/clpt.2009.181

Hiroyuki Akita - One of the best experts on this subject based on the ideXlab platform.